文献速递消化系统肿瘤

MODUL试验(队列1、3和4)中转移性结直肠癌生物标志物驱动维持治疗的临床与探索性生物标志物发现

Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2023-02-04

MODUL是一项适应性信号探索试验,评估转移性结直肠癌一线诱导后生物标志物驱动维持治疗。队列1(BRAF突变)实验组与对照组无进展生存无显著差异(HR 0.95, 95%CI 0.50-1.82, P=0.872);队列3(HER2阳性)样本量仅5例;队列4(HER2阴性/MSS/BRAF野生型)实验组无进展生存更短(HR 1.44, 95%CI 0.90-2.29, P=0.128)。结论认为维莫非尼联合西妥昔单抗联合5-FU/LV值得进一步研究,而考比替尼联合阿替利珠单抗在HER2阴性/MSS/BRAF野生型mCRC中获益风险比不利。

要点

  • 队列1(BRAF突变)实验组与对照组PFS无显著差异(HR 0.95, 95%CI 0.50-1.82, P=0.872)。
  • 队列1探索性生物标志物显示实验组优先选择MAPK通路突变(主要为KRAS、NRAS、MAP2K1或BRAF)。
  • 队列4(HER2阴性/MSS/BRAF野生型)实验组PFS更短(HR 1.44, 95%CI 0.90-2.29, P=0.128)。

核心结论

  • 维莫非尼联合西妥昔单抗联合5-FU/LV作为BRAF突变mCRC一线维持治疗值得进一步研究。
  • MAPK通路新发基因组改变可能为BRAF突变mCRC提供新的治疗机会。
  • 考比替尼联合阿替利珠单抗在HER2阴性/MSS/BRAF野生型mCRC中获益风险比不利。
  • 需要新策略来提高MSS mCRC对免疫治疗的敏感性。

研究设计与样本

  • MODUL是一项适应性、信号探索性试验,评估mCRC一线诱导治疗后生物标志物驱动维持治疗。
  • 患者为不可切除、既往未治疗且标准诱导治疗(5-FU/LV+奥沙利铂+贝伐珠单抗)后无疾病进展的mCRC。
  • 患者随机分配至对照组(氟嘧啶+贝伐珠单抗)或队列特异性实验维持治疗。
  • 队列1(BRAF突变)实验组为维莫非尼+西妥昔单抗+5-FU/LV;队列3(HER2阳性)为卡培他滨+曲妥珠单抗+帕妥珠单抗;队列4为考比替尼+阿替利珠单抗。
  • 主要疗效终点为无进展生存(PFS)。

主要发现

  • 队列1、3和4因研究提前终止未达到目标样本量。
  • 队列1(n=60)实验组与对照组PFS无差异(HR 0.95, 95%CI 0.50-1.82, P=0.872)。
  • 队列1探索性生物标志物显示实验组优先选择MAPK通路突变(主要为KRAS、NRAS、MAP2K1或BRAF),对照组无此现象。
  • 队列3(n=5)实验组PFS范围3.6至14.7个月,对照组4.0至5.4个月。
  • 队列4(n=99)实验组PFS更短(HR 1.44, 95%CI 0.90-2.29, P=0.128)。

临床怎么用

  • 作者认为维莫非尼联合西妥昔单抗联合5-FU/LV作为BRAF突变mCRC一线维持治疗值得进一步研究。
  • 作者指出MAPK通路新发基因组改变可能为BRAF突变mCRC提供新的治疗机会。
  • 作者认为考比替尼联合阿替利珠单抗在HER2阴性/MSS/BRAF野生型mCRC中获益风险比不利。
  • 作者提出需要新策略来提高MSS mCRC对免疫治疗的敏感性。

局限性

  • 队列1、3和4因研究提前终止未达到目标样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: MODUL is an adaptable, signal-seeking trial of biomarker-driven maintenance therapy following first-line induction treatment in patients with metastatic colorectal cancer (mCRC). We report findings from Cohorts 1 (BRAFmut), 3 (human epidermal growth factor 2 [HER2]+) and 4 (HER2‒/high microsatellite instability, HER2‒/microsatellite stable [MSS]/BRAFwt or HER2‒/MSS/BRAFmut/RASmut). METHODS: Patients with unresectable, previously untreated mCRC without disease progression following standard induction treatment (5-fluorouracil/leucovorin [5-FU/LV] plus oxaliplatin plus bevacizumab) were randomly assigned to control (fluoropyrimidine plus bevacizumab) or cohort-specific experimental maintenance therapy (Cohort 1: vemurafenib plus cetuximab plus 5-FU/LV; Cohort 3: capecitabine plus trastuzumab plus pertuzumab; Cohort 4: cobimetinib plus atezolizumab). The primary efficacy end-point was progression-free survival (PFS). RESULTS: Cohorts 1, 3 and 4 did not reach target sample size because of early study closure. In Cohort 1 (n = 60), PFS did not differ between treatment arms (hazard ratio, 0.95; 95% confidence intervals 0.50-1.82; P = 0.872). However, Cohort 1 exploratory biomarker data showed preferential selection for mitogen-activated protein kinase (MAPK) pathway mutations (mainly KRAS, NRAS, MAP2K1 or BRAF) in the experimental arm but not the control arm. In Cohort 3 (n = 5), PFS ranged from 3.6 to 14.7 months versus 4.0 to 5.4 months in the experimental and control arms, respectively. In Cohort 4 (n = 99), PFS was shorter in the experimental arm (hazard ratio, 1.44; 95% confidence intervals 0.90-2.29; P = 0.128). CONCLUSIONS: Vemurafenib plus cetuximab plus 5-FU/LV warrants further investigation as first-line maintenance treatment for BRAFmut mCRC. MAPK-pathway emergent genomic alterations may offer novel therapeutic opportunities in BRAFmut mCRC. Cobimetinib plus atezolizumab had an unfavourable benefit:risk ratio in HER2‒/MSS/BRAFwt mCRC. New strategies are required to increase the susceptibility of MSS mCRC to immunotherapy. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02291289.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Ducreux M, Tabernero J, Grothey A, et al. Clinical and exploratory biomarker findings from the MODUL trial (Cohorts 1, 3 and 4) of biomarker-driven maintenance therapy for metastatic colorectal cancer. Eur J Cancer. 2023. PMID: 36921494. doi:10.1016/j.ejca.2023.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。